{"entity":{"id":"idea-fund-academic-radiopharma-pipeline","kind":"idea","name":"A university cyclotron network with shared regulatory files for new tracers","aka":[],"tldr":"Most new cancer imaging agents and radioactive drugs start in university hospitals. A network sharing production, quality files and regulatory paperwork would get them into multi-centre trials years faster.","summary":"Academic radiopharmacy has repeatedly produced the agents the field now runs on (PSMA ligands and FAPI tracers from Heidelberg, DOTATATE from Basel and Rotterdam) but each centre re-creates production, quality control and regulatory documentation. A funded network of university cyclotrons and radiopharmacies would share drug master files, validated synthesis modules, GMP quality systems and a common clinical trial application template, so a tracer validated in one centre can be adopted in ten within months. It would also provide isotope purchasing at scale (gallium-68 generators, lutetium-177, actinium-225 allocation) for academic trials.","asOf":"2026-09-08","links":[{"label":"Bottleneck evidence (The valley of death between lab and product): Butler, Translational research: crossing the valley of death (Nature 2008)","url":"https://doi.org/10.1038/453840a"}],"tags":[],"related":["idea-fund-phase-zero-fund","idea-fap-theranostics-pancancer","radiopharma-roadmap"],"cancers":[],"sections":[],"technologies":["psma-pet","fapi-pet","radioligand-therapy","targeted-alpha-therapy"],"targets":[],"drugs":[],"companies":[],"institutions":["heidelberg-nct","dkfz","peter-mac"],"pathways":[],"terms":[],"trials":[],"people":["uwe-haberkorn","frederik-giesel","hofman-michael"],"bottlenecks":["b-translational-valley","b-manufacturing-cell-therapy"],"keyPapers":["paper-butler-nature"],"journals":[],"dependsOn":[],"notes":[],"hypothesis":"A shared network reduces the time from first-in-human of an academic tracer or radioligand to a five-centre trial from the current several years to under eighteen months, and doubles the number of academic radiopharmaceuticals entering multi-centre trials within four years.","rationale":"PSMA PET spread globally because academic centres shared precursors and methods informally; formalising that with shared regulatory files removes the largest delay. Germany's and the Netherlands' academic radiopharmacy networks demonstrate feasibility within a country.","test":"Fund a ten-centre network with a shared master file for two agents and measure time to multi-centre trial start and centres activated compared with agents developed without the network.","maturity":"early-clinical","actor":"research","cost":"medium","horizonYears":4},"route":"/ideas/idea-fund-academic-radiopharma-pipeline/","neighbours":{"idea":[{"id":"idea-fund-phase-zero-fund","kind":"idea","name":"A phase 0 fund to test academic compounds in humans with microdoses and imaging","route":"/ideas/idea-fund-phase-zero-fund/"},{"id":"idea-fap-theranostics-pancancer","kind":"idea","name":"FAP theranostics as a pan-cancer stromal strategy","route":"/ideas/idea-fap-theranostics-pancancer/"}],"roadmap":[{"id":"radiopharma-roadmap","kind":"roadmap","name":"Radiopharmaceutical roadmap: iodine → lutetium → actinium","route":"/roadmaps/radiopharma-roadmap/"}],"technology":[{"id":"fapi-pet","kind":"technology","name":"FAPI PET","route":"/technologies/fapi-pet/"},{"id":"psma-pet","kind":"technology","name":"PSMA PET","route":"/technologies/psma-pet/"},{"id":"radioligand-therapy","kind":"technology","name":"Radioligand therapy (beta emitters)","route":"/technologies/radioligand-therapy/"},{"id":"targeted-alpha-therapy","kind":"technology","name":"Targeted alpha therapy","route":"/technologies/targeted-alpha-therapy/"}],"institution":[{"id":"dkfz","kind":"institution","name":"German Cancer Research Center (DKFZ)","route":"/institutions/dkfz/"},{"id":"heidelberg-nct","kind":"institution","name":"Heidelberg University Hospital / NCT / DKFZ","route":"/institutions/heidelberg-nct/"},{"id":"peter-mac","kind":"institution","name":"Peter MacCallum Cancer Centre","route":"/institutions/peter-mac/"}],"person":[{"id":"frederik-giesel","kind":"person","name":"Frederik Giesel","route":"/people/frederik-giesel/"},{"id":"hofman-michael","kind":"person","name":"Michael Hofman","route":"/people/hofman-michael/"},{"id":"uwe-haberkorn","kind":"person","name":"Uwe Haberkorn","route":"/people/uwe-haberkorn/"}],"bottleneck":[{"id":"b-manufacturing-cell-therapy","kind":"bottleneck","name":"Manufacturing cost and time for living and radioactive medicines","route":"/bottlenecks/b-manufacturing-cell-therapy/"},{"id":"b-translational-valley","kind":"bottleneck","name":"The valley of death between lab and product","route":"/bottlenecks/b-translational-valley/"}],"paper":[{"id":"paper-butler-nature","kind":"paper","name":"Translational research: crossing the valley of death","route":"/key-papers/paper-butler-nature/"}]}}